Medidata and the National Cancer Institute Extend 15-Year Partnership for an Additional Five Years

Medidata announced a five-year extension of its partnership with the National Cancer Institute, building on 15 years of collaboration since 2008 supporting thousands of oncology clinical trials. The page states '90% of all oncology approvals last year in the U.S. were developed using Medidata software,' and that Medidata's solutions can accelerate studies by up to five months. It also cites the platform standardizing processes and data collection across more than 3,000 academic clinical trials, 223,000 sites, and 948,000 patients.

Medidata is a Dassault Systèmes company supplying the clinical-trial EDC and data platform (Rave) most sponsors and CROs already run live trials on, now with an AI layer built in.

This sits in the Ship stage of the AI use-case lifecycle: Named examples from the vendors pharma teams use to get an AI system live inside a real, regulated production workflow — validation, CRM, safety and clinical systems of record.